:: Volume 29, Issue 2 (Summer 2019) ::
MEDICAL SCIENCES 2019, 29(2): 117-124 Back to browse issues page
Formulation and in vitro evaluation of orally disintegrating film of alprazolam
Zahra Jafariazar1 , Seyed Kazem Sadjady1 , Niloufar Chamani2 , Minoo Afshar 3
1- Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University (IAU), Tehran, Iran
2- Pharm.D. Student, Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University (IAU), Tehran, Iran
3- Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University (IAU), Tehran, Iran , afsharme@ sina.tums.ac.ir
Abstract:   (3911 Views)
Background: Over the past years, orally disintegrating films (ODFs) have been a suitable alternative to conventional oral dosage forms such as tablets and capsules, especially for patients with dysphagia. ODF is relatively a new dosage form which is prepared using hydrophilic polymers, which rapidly dissolve on tongue or buccal cavity and has other advantages of rapid onset of action and improved bioavailability. The aim of this study was formulation of ODF dosage forms containing alprazolam, which is a short-acting anxiolytic of the benzodiazepines class of psychoactive drugs.
Materials and methods: Various polymers like hydroxy propyl methyl cellulose (HPMC6cps), sodium carboxy methyl cellulose (Na CMC), polyvinyl alcohol (PVA72000), and different plasticizers like propylene glycol (PG), polyethylene glycol (PEG400) with different percentage using solvent casting technique were used to prepare ODF formulations. Physicochemical tests including weight and thickness determination, disintegration time, assay and dissolution time were performed to find the optimum formulation.
Results: The optimized formulation contained PVA72000 and PEG400 with disintegration time less than 60 seconds and acceptable dissolution rate.
Conclusion: ODT dosage form of alprazolam with acceptable dissolution behavior and proper disintegration time was successfully formulated in this study.
Keywords: Alprazolam, Orally disintegrating films, Formulation, In vitro evaluation
Keywords: Alprazolam, Orally disintegrating films, Formulation, In vitro evaluation
Full-Text [PDF 749 kb]   (3041 Downloads)    
Semi-pilot: Experimental | Subject: Pharmacology
Received: 2018/12/19 | Accepted: 2019/01/13 | Published: 2019/06/16
References
1. Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul 2008;2:258-74. [DOI:10.2174/187221108786241660] [PMID]
2. Lee Y, Thapa P, Jeong SH, Woo MH, Choi DH. Formulation Optimization and in Vitro Characterization of Orally Disintegrating Films Using a Factorial Design and Mathematical Modeling for Drug Release. Chem Pharm Bull (Tokyo) 2017;65:166-77. [DOI:10.1248/cpb.c16-00757] [PMID]
3. Malallah OS, Garcia CMA, Proctor GB, Forbes B, Royall PG. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth). Int J Pharm 2018;541:157-66. [DOI:10.1016/j.ijpharm.2018.02.004] [PMID]
4. Isbister GK, O'Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 2004;58:88-95. [DOI:10.1111/j.1365-2125.2004.02089.x] [PMID] [PMCID]
5. Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, et al. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 2008;3:e2337 [DOI:10.1371/journal.pone.0002337] [PMID] [PMCID]
6. Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS PharmSciTech 2008;9:349-56. [DOI:10.1208/s12249-008-9047-7] [PMID] [PMCID]
7. Samprasit W, Akkaramongkolporn P, Kaomongkolgit R, Opanasopit P. Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam. Pharm Dev Technol 2017;7:1-10. [DOI:10.1080/10837450.2017.1401636] [PMID]
8. Liu C, Chang D, Zhang X, Sui H, Kong Y, Zhu R, et al. Oral fast-dissolving films containing lutein nanocrystals for improved bioavailability: formulation development, in vitro and in vivo evaluation. AAPS PharmSciTech 2017;18:2957-64. [DOI:10.1208/s12249-017-0777-2] [PMID]
9. Garsuch V. Preparation and characterization of fast-dissolving oral films for pediatric use [PhD dissertation]. Düsseldorf: Heinrich-Heine University; 2009.
10. United States Pharmacopeia (USP): 2019. Available from: https://www.uspnf.com/sites/default/files/ usp_pdf/EN/USPNF/revisions/alprazolam-tabs-rb-notice-20190301.pdf
11. Londhe VY, Umalkar KB. Formulation development and evaluation of fast dissolving film of telmisartan. Indian J Pharm Sci 2012;74:122-6. [DOI:10.4103/0250-474X.103842]
12. Dahiya M, Saha S, Shahiwala AF. A review on mouth dissolving films. Curr Drug Deliv 2009;6:469-76. [DOI:10.2174/156720109789941713] [PMID]
13. Kathpalia H, Gupte A. An introduction to fast dissolving oral thin film drug delivery systems: a review. Curr Drug Deliv 2013;10:667-84. [DOI:10.2174/156720181006131125150249] [PMID]
14. Rabinowitz JD, Lloyd PM, Munzar P, Myers DJ, Cross S, Damani R, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 2006;95:2438-51. [DOI:10.1002/jps.20694] [PMID]
15. RxList website. https://www.rxlist.com/xanax-drug.htm
16. Oo CY, Kuhn RJ, Desai N, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Br J Clin Pharmacol 1995;40:231-6. [DOI:10.1111/j.1365-2125.1995.tb05778.x] [PMID]
17. Pacheco PA, Rodrigues LNC, Ferreira JFS, Gomes ACP, Veríssimo CJ, Louvandini H, et al. Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole. Parasitol Res 2018;117:705-12. [DOI:10.1007/s00436-017-5740-3] [PMID]



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 29, Issue 2 (Summer 2019) Back to browse issues page